Consumer Data Privacy Act Passed by Senate, but Dies in House

December 31, 2024

Michigan's Personal Data Privacy Act Advances, Raising Stakes for Medtech Industry

The Michigan Senate passed the Personal Data Privacy Act (SB 659) along party lines in lame duck session, moving Michigan a step closer to joining the growing ranks of states that have approved comprehensive privacy and data protection legislation. But the legislation didn’t get taken up by the House and died, meaning that the measure is likely to be reintroduced in 2025.

It would, among other provisions, give consumers the right to opt out of the processing of their personal data for targeted advertising, the sale of personal data, and specified profiling activities, as well as confer data rights found in other states’ laws, including rights of access, correction, deletion, and data portability.


MichBio, along with its partner, AdvaMed, advocated long for inclusion of the following exemption: Sec.11 (3): Information included in a Limited Data Set as described at 45 CFR 164.514(e), to the extent that the information is used, disclosed, and maintained in the manner specified at 45CFR 164.514(e).



That legal speak is a critical inclusion and would permit the transfer of research data between parties and avoid negatively impacting patient care and research and development, especially on the part of medical device manufacturers.


There is no way for medical device manufacturers to tell whether data from certain devices technically falls outside of HIPAA, so all data is treated as though it is protected under HIPAA. The proposed exemption enables medtech companies to continue to support patient care uniformly.


For example, patient data from cardiac monitors used by HCPs who are Covered Recipients under HIPAA is excluded, while patient data from the same model cardiac monitors used by concierge physicians is regulated as health data under this bill with respect to the medtech company even though the company treats data from both devices in the same way.


MichBio and AdvaMed tried to point out that certain consumer rights and regulated entity obligations are inconsistent with how medical devices are utilized in patient care. We expect the bill will be reintroduced in early 2025.

RECENT ARTICLES

April 7, 2025
Accelerate Growth with Expert Leadership & Exclusive Savings Through MichBio’s BiotechExec Program
April 7, 2025
MMS Holdings has earned the prestigious 2025 Data Breakthrough Award for "Best Data Science Solution" with its innovative Datacise® platform. This cloud-based solution empowers pharmaceutical and biotech companies to efficiently analyze, visualize, and manage clinical and real-world data, accelerating drug development and decision-making. Datacise offers cutting-edge features such as real-time data monitoring, enhanced diversity planning, operational reporting, and faster access to top-line clinical trial data. These capabilities streamline processes, improve trial adaptability, and ensure regulatory compliance, showcasing MMS’s commitment to advancing data-driven solutions for complex drug development challenges. With nearly two decades of experience and a global presence, MMS continues to be a trusted partner for the life sciences industry.  For further details on this award-winning platform, read the full press release .
March 28, 2025
Secure Your Spot at The MedTech Conference 2025 with MichBio!
Share by: